- Temporary policy for manufacture of alcohol for incorporation into alcohol-based hand sanitizer products during the public health emergency (COVID-19)1
- Temporary policy for preparation of certain alcohol-based hand sanitizer products during the public health emergency (COVID-19)2
- Temporary policy on Prescription Drug Marketing Act requirements for distribution of drug samples during the COVID-19 public health emergency1
- Temporary policy on repackaging or combining propofol drug products during the COVID-19 public health emergency1
- Temporary policy regarding accredited third-party certification program onsite observation and certificate duration requirements during the COVID-19 public health emergency1
- Temporary policy regarding non-standard PPE practices for sterile compounding by pharmacy compounders not registered as outsourcing facilities during the COVID-19 public health emergency1
- Temporary policy regarding preventive controls and FSVP food supplier verification onsite audit requirements during the COVID-19 public health emergency: guidance for industry1
- Tennessee Medicaid Fraud Control Unit: 2017 onsite inspection1
- Testimony by Harold Varmus, MD, to the Senate Judiciary Committee Hearing on Human Cloning1
- Testimony of Harold Varmus, MD. . . . House Committee on Energy and Commerce and Senate Committee on Health, Education, Labor, and Pensions: "Managing Biomedical Research to Prevent and Cure Disease in the 21st Century: Matching NIH Policy with Science"1
- Testimony of Paul Berg, PhD, to the Senate Judiciary Committee Hearing [on Human Cloning]1
- Testing and labeling medical devices for safety in the magnetic resonance (MR) environment: guidance for industry and Food and Drug Administration staff1
- Testing for biotin interference in in vitro diagnostic devices1
- Testing of glycerin, propylene glycol, maltitol solution, hydrogenated starch hydrolysate, sorbitol solution, and other high-risk drug components for diethylene glycol and ethylene glycol: guidance for industry1
- Testing of retroviral vector-based human gene therapy products for replication competent retrovirus during product manufacture and patient follow-up1
- The "deemed to be a license" provision of the BPCI Act: questions and answers1
- The 'New Federalism' and Public Health: Keynote Address to the 18th Annual Conference of the New England Public Health Association, Wychmere Harbor, Cape Cod, Massachusetts [Reminiscence]1
- The 2018 long-term budget outlook1
- The 2019 long-term budget outlook1
- The Accreditation Scheme for Conformity Assessment (ASCA) Pilot Program: guidance for industry, accreditation bodies, testing laboratories, and Food and Drug Administration staff1